OMIC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OMIC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Singular Genomics Systems's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $1.14 Mil. Singular Genomics Systems's average total debt for the quarter that ended in Mar. 2024 was $74.41 Mil. Therefore, Singular Genomics Systems's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 1.53%.
The historical data trend for Singular Genomics Systems's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Singular Genomics Systems Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Effective Interest Rate on Debt % | 0.71 | 12.17 | 8.77 | 2.22 | 1.64 |
Singular Genomics Systems Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | 1.76 | 1.85 | 1.68 | 1.51 | 1.53 |
For the Medical Instruments & Supplies subindustry, Singular Genomics Systems's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Singular Genomics Systems's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Singular Genomics Systems's Effective Interest Rate on Debt % falls into.
Singular Genomics Systems's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (A: Dec. 2022 ) | + | Total Debt (A: Dec. 2023 )) | / count ) |
= | -1 * -1.101 | / | ( (58.844 | + | 75.288) | / 2 ) |
= | -1 * -1.101 | / | 67.066 | |||
= | 1.64 % |
where
Total Debt (A: Dec. 2022 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 52.521 | + | 6.323 |
= | 58.844 |
Total Debt (A: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 67.524 | + | 7.764 |
= | 75.288 |
Singular Genomics Systems's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (Q: Dec. 2023 ) | + | Total Debt (Q: Mar. 2024 )) | / count ) |
= | -1 * -1.136 | / | ( (75.288 | + | 73.541) | / 2 ) |
= | -1 * -1.136 | / | 74.4145 | |||
= | 1.53 % |
where
Total Debt (Q: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 67.524 | + | 7.764 |
= | 75.288 |
Total Debt (Q: Mar. 2024 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 65.719 | + | 7.822 |
= | 73.541 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.
Singular Genomics Systems (NAS:OMIC) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Thank you for viewing the detailed overview of Singular Genomics Systems's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew Spaventa | director, 10 percent owner, officer: Chief Executive Officer | 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Eli N. Glezer | officer: Chief Scientific Officer | 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Jyotsna Ghai | officer: Chief Operating Officer | 3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
Kim P. Kamdar | director | C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542 |
Marcia Eisenberg | director | C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210 |
Sam Ropp | officer: Chief Commercial Officer | 3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
Michael J Pellini | director | 222 DUTTON MILL RD, WILLISTOWN PA 19380 |
Elaine R Mardis | director | 301 MERRITT 7, NORWALK CT 06851 |
James E Flynn | 10 percent owner, other: *Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
David Daly | officer: President and Chief Operating | 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Vincent Brancaccio | officer: Vice President, HR | 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Dalen Meeter | officer: Vice President, Finance | 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Daralyn Durie | officer: General Counsel | 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Jorge Velarde | officer: Senior Vice President | 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
David L Barker | director | 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121 |
From GuruFocus
By Value_Insider Value_Insider • 10-24-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By GlobeNewswire • 01-07-2024
By PurpleRose PurpleRose • 07-13-2022
By Stock market mentor Stock market mentor • 02-06-2023
By Stock market mentor Stock market mentor • 02-02-2023
By Marketwired • 08-08-2023
By Marketwired • 10-24-2023
By PurpleRose PurpleRose • 08-18-2022
By Marketwired • 07-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.